Staying Ahead: Advanced Monitoring and Risk Assessment
At a Glance
EKC syndrome requires personalized, lifelong heart surveillance. ECGs, Holter monitors, echocardiograms, and cardiac MRI track rhythm, pumping function, and scar tissue, while DSP risk markers help specialists discuss monitoring intensity and whether an ICD may be appropriate.
Living with Erythrokeratodermia-cardiomyopathy (EKC) syndrome means becoming a lifelong partner in your own medical monitoring. Because the heart risks associated with the DSP gene can be progressive and sometimes “silent,” doctors use advanced tools to predict your risk and stay ahead of any changes [1][2].
The DSP Arrhythmic Risk Score
Some specialists may reference a research-derived DSP-specific risk score to supplement their electrophysiology assessment. This tool accounts for the unique way DSP affects the heart muscle, though it does not replace a doctor’s clinical judgment [2].
The score looks at five specific clinical variables to calculate your “5-year predicted risk” [2]:
- Biological Sex: Female sex is associated with a higher risk of heart rhythm issues in this specific condition [2][3].
- NSVT (Nonsustained Ventricular Tachycardia): A history of short bursts of rapid heartbeats discovered on a Holter monitor [2].
- 24-Hour PVC Burden: The total number of extra heartbeats (premature ventricular contractions) recorded in one day [2].
- LVEF < 50%: A measurement showing that the left side of the heart is pumping at less than 50% of its normal capacity [2][3].
- RV Systolic Dysfunction: Signs that the right side of the heart is struggling to pump effectively [2].
What the Score Means
This tool helps your doctor decide if you need an ICD (Implantable Cardioverter-Defibrillator). While early studies showed a high negative predictive value for patients in the lowest risk group, a predicted risk below 5% is not absolute assurance that a patient will remain safe. Risk can change, which is why regular ongoing surveillance is important, alongside other clinical markers like scar burden (LGE) [4].
Your Surveillance Schedule
While your schedule will be personalized by your specialist, the following table represents an illustrative example of testing frequencies for many people with EKC. The treating team sets the actual interval based on age, symptoms, prior arrhythmias, and ventricular function [4][5]:
| Test | Frequency | What It Looks For |
|---|---|---|
| ECG (Electrocardiogram) | Every 6–12 months | Changes in electrical signals, like T-wave inversions [3]. |
| 24-Hour Holter Monitor | Every 6–12 months | Your daily “PVC burden” and any hidden bursts of NSVT [2]. |
| Echocardiogram | Every 12 months | Overall heart size and pumping strength (LVEF) [4]. |
| Cardiac MRI (CMR) | Every 1–3 years | New areas of scar tissue (LGE) or inflammation (edema) [6]. |
Note: If you experience a “hot phase” (chest pain and myocardial injury), your doctor may move these tests forward to check for new damage to the heart muscle [3][7]. Repeated gadolinium-enhanced CMR and sedation in children require individualized risk-benefit decisions.
Managing “Scanxiety” and the Psychological Toll
It is completely normal to feel a sense of dread or high anxiety—often called scanxiety—in the days or weeks leading up to your scheduled heart tests. Living with the knowledge that you have a condition requiring active surveillance can feel stressful [8].
- Acknowledge the Stress: Recognize that these tests are a heavy emotional lift. They are not just medical check-ups; they are reminders of your condition’s potential risks.
- The Power of Knowledge: Shift your perspective when possible. Each scan is not just a search for bad news, but a vital piece of data that allows your team to keep you safe. In the rare disease world, being “well-monitored” is a form of protection [8].
- Routine as a Tool: Many families find that having a set routine for “scan days” (like a favorite meal afterward) helps make the process feel more manageable and less like a crisis.
If the anxiety of monitoring begins to interfere with your ability to enjoy your life, please speak with your care team. Many specialized heart centers have cardio-psychologists who understand the unique intersection of heart health and mental well-being [8].
Common questions in this guide
What does the DSP arrhythmic risk score tell me?
How often might I need heart tests for EKC syndrome?
Does a DSP risk estimate below 5% mean I am safe?
What does a rising PVC burden or NSVT finding mean?
What should happen after a hot phase or chest pain episode?
How can I manage anxiety about repeated heart tests?
Get notified when new evidence is published on Erythrokeratodermia-cardiomyopathy syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Dominant de novo DSP mutations cause erythrokeratodermia-cardiomyopathy syndrome.
Boyden LM, Kam CY, Hernández-Martín A, et al.
Human molecular genetics 2016; (25(2)):348-57 doi:10.1093/hmg/ddv481.
PMID: 26604139 - 2
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers.
Carrick RT, Gasperetti A, Protonotarios A, et al.
European heart journal 2024; (45(32)):2968-2979 doi:10.1093/eurheartj/ehae409.
PMID: 39011630 - 3
Clinical features and outcomes in carriers of pathogenic desmoplakin variants.
Gasperetti A, Carrick RT, Protonotarios A, et al.
European heart journal 2025; (46(4)):362-376 doi:10.1093/eurheartj/ehae571.
PMID: 39288222 - 4
Diagnostic Criteria and Disease Staging for Desmoplakin Cardiomyopathy.
Smith E, Gasperetti A, Carrick RT, et al.
medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.06.16.25329734.
PMID: 40666337 - 5
Recurrent Ventricular Tachycardia in a Young Adult-Imaging and Genetic Evidence of DSP-Associated Arrhythmogenic Cardiomyopathy: A Case Report.
Gomez LE, Martinenghi N, Ortiz-Genga M, et al.
Case reports in cardiology 2026; (2026()):5899286 doi:10.1155/cric/5899286.
PMID: 41953707 - 6
Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy.
Smith ED, Lakdawala NK, Papoutsidakis N, et al.
Circulation 2020; (141(23)):1872-1884 doi:10.1161/CIRCULATIONAHA.119.044934.
PMID: 32372669 - 7
Clinical characteristics and risk stratification of desmoplakin cardiomyopathy.
Wang W, Murray B, Tichnell C, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(2)):268-277 doi:10.1093/europace/euab183.
PMID: 34352074 - 8
Imaging Naxos disease and related cardiocutaneous syndromes: the NAXCARE multimodality approach.
Protonotarios I, Alsergani H, Anastasakis A, et al.
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2026; doi:10.1016/j.hjc.2026.03.007.
PMID: 41936932
This page is for informational purposes only and does not constitute medical advice. Your cardiology and electrophysiology team should personalize your EKC surveillance schedule and discuss any ICD decision with you.